BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
|Closed|| Long (1Y)
Religare maintains hold on Sun Pharmaceutical Industries
Sun Pharma's in-licensed molecule from Merck, Tildrakizumab (Tildra), evaluated for treating moderate-to-severe plaque psoriasis, has met primary endpoints in phase-3 clinical trials. This is an important milestone for Sun Pharma and paves the way for its NDA filing in CY17. Target price remains unchanged on factoring in losses from cessation of Keveyis sales, which was halted recently.